Skip to main content
Premium Trial:

Request an Annual Quote

Lophius Joins Germany-funded Effort to Develop MS Dx

NEW YORK (GenomeWeb News) – Lophius Biosciences today said that it has joined a research consortium that will work with the firm on developing its T-Track MS diagnostic test for initial diagnosis of multiples sclerosis and monitoring of disease progression.

The project is part of the NEU2 program and has received funding of €350,000 ($468,800) from Germany's Federal Ministry of Education and Research.

Lophius is developing a T-cell-based diagnostic test kit for MS, which it believes will fill an unmet clinical need by offering a rapid blood-based test for differential diagnosis of the disease. The test is based on the firm's Reverse T Cell Technology platform, which "exploits the maturation processes induced in antigen presenting cells via a specific interaction with activated T helper cells thus representing an indirect measure for activated Th cells," the firm said in a statement.

"Both the opportunity to interact with leading experts in the MS field as well as the substantial funding will accelerate the development of our highly innovative T cell based diagnostic T-Track MS test kit and help Lophius to initiate a broader clinical discovery and development program," Michael Lutz and Ralf Wagner, managing directors of Regensburg, Germany-based Lophius Biosciences, said.

The NEU2 program was created to initiate collaborations between academic institutions, biotech, and pharmaceutical companies in Germany. It is coordinated by Bionamics and has a particular focus on developing therapeutics for multiple sclerosis.

Earlier this year Lophius raised $5.3 million in a private financing round.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.